Financial Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance byJosh SandbergNovember 7, 2023
Extremities Top Stories Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System byJosh SandbergSeptember 11, 2023
Financial Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance byJosh SandbergAugust 2, 2023
Extremities Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System byJosh SandbergMay 23, 2023
Financial Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance byJosh SandbergMay 5, 2023
Financial Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance byJosh SandbergMarch 2, 2023
Financial Paragon 28, Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock byJosh SandbergFebruary 17, 2023
Financial Paragon 28, Inc. Announces Proposed Public Offering of Common Stock byJosh SandbergJanuary 25, 2023
Financial Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022 byChris StewartJanuary 10, 2023
